Dr. Reddy's Laboratories
Dr. Reddy's Laboratories is an Indian multinational pharmaceutical company based in Hyderabad. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy manufactures and markets a wide range of pharmaceuticals in India and overseas. The company produces over 190 medications, 60 active pharmaceutical ingredients (APIs) for drug manufacture, diagnostic kits, critical care, and biotechnology.
| Company type | Public |
|---|---|
Traded as | NSE: DRREDDY BSE: 500124 NYSE: RDY NSE NIFTY 50 Constituent |
| ISIN | INE089A01023 |
| Industry | Pharmaceuticals |
| Founded | 1984 |
| Founders | Anji Reddy |
| Headquarters | Hyderabad; Telangana, India |
Area served | Worldwide |
Key people | G. V. Prasad (Co-Chairman & MD) Kallam Satish Reddy (Chairman) Erez Israeli (CEO) |
| Products | Pharmaceuticals, generic drugs, over-the-counter drugs, vaccines, diagnostics, Biologics |
| Revenue | ₹25,725 crore (US$3.2 billion) (2023) |
| ₹6,011 crore (US$750 million) (2023) | |
Net income | ₹4,470 crore (US$560 million) (2023) |
| Total assets | ₹23,156 crore (US$2.9 billion) (2023) |
| Total equity | ₹23,286 crore (US$2.9 billion) (2023) |
Number of employees | 24,832 (March 2023) |
| Website | www |
Dr. Reddy's began as a supplier to Indian drug manufacturers, but it soon started exporting to other less-regulated markets that had the advantage of not having to spend time and money on a manufacturing plant that would gain approval from a drug licensing body such as the U.S. Food and Drug Administration (FDA). By the early 1990s, the expanded scale and profitability from these unregulated markets enabled the company to begin focusing on getting approval from drug regulators for their formulations and bulk drug manufacturing plants – in more-developed economies. This allowed their movement into regulated markets such as the US and Europe.
By 2007, Dr. Reddy's had seven FDA plants producing active pharmaceutical ingredients in India and seven FDA-inspected and ISO 9001 (quality) and ISO 14001 (environmental management) certified plants making patient-ready medications – five of them in India and two in the UK.